Navigation Links
genae Appoints Chief Medical Officer
Date:4/16/2012

ANTWERP, Belgium, April 16, 2012 /PRNewswire/ --

genae, a leading Contract Research Organization (CRO) and services provider for the medical device industries, today announced that Catalina Trana, MD, has been appointed Chief Medical Officer. In this role, Dr. Trana will be responsible for all clinical, safety and risk management related to genae's research services.

"I am delighted to welcome Catalina, whose extensive clinical and research expertise will be of great benefit to the many aspects of our services offering," said Bart Segers, Chairman and CEO of genae. "We believe that her experience as an interventional cardiologist provides her with a unique opportunity to view our services with an unsurpassed balance of clinical insight, business acumen and regulatory and safety compliance.

Dr. Trana holds the position of Cardiology Specialist at the Interventional Cardiology Department of the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. She was a fellow at the Cardiovascular Center Aalst, OLVZ, Aalst, Belgium and worked and trained at the Interventional Cardiology Department and Cardiovascular Surgical Department of the Cardiovascular Center in Iasi, Romania; and at the Catholic University of Leuven, Belgium. Her scientific and research work is illustrated by peer-reviewed publications and presentations during international congresses and symposia.

About genae

genae is a full service CRO and an innovative services provider for the medical industries and aims at improving health and quality of life by innovating and accelerating high quality research. The group is ISO 9001 certified for Clinical Trial Management, Core Laboratory Services and Additional Services for the Medical Industries.

genae associates nv is a privately held company with principal offices in Antwerp, Belgium.

genae Americas Inc. is a privately held company with principal offices in Cleveland, OH.

Please visit:
'/>"/>

SOURCE genae associates nv
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
2. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
3. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
4. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
6. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
7. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
8. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
11. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/18/2013)... In a May 14, 2013 article entitled “Angelina Jolie ... Gene,” Fox News reported the movie star had opted ... a gene that doctors estimated gave her an 87 ... risk of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s ... a blog post entitled “A Patient’s Journey: Angelina Jolie” ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... 2013 TheBeautyPlace.com answers important questions about ... is not a result of stress, nutrient deficiency or ... Magazine, 70% of men suffer from male patterned baldness. ... renowned for hair transplant surgery, but additionally carries a ... known as Bosley Professional Strength. Their product line is ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3
... Cancer Research Foundation, IRVING, Texas, Oct. 12 ... October in honor of Breast,Cancer Awareness Month. The pieces ... pink initiative come in both necklaces and earrings,and are ... collection are,being donated to The Breast Cancer Research Foundation. ...
... Oct. 11 A recent study from the Centers ... U.S. workers with,arthritis suffered work limitations in 2003. ... to,comment on this study: Stephen Paget, MD, FACP, ... for Special Surgery, is available to,talk about the causes ...
... Sutter Health and an agency,that is supplying ... law --,and jeopardizing public health -- by failing ... validation to be working in hospitals where,the regular ... Nurses Organizing Committee today. In addition to ...
... Md., Oct. 11 /Xinhua-PRNewswire/ -- On,October 10, 2007, ... leading manufacturers of dairy-based nutritional products,for infants, children ... Stock,Market stating that the Company,s common stock is ... the SEC on October 5, 2007 of the,Company,s ...
... of Kohn, Swift &,Graf, P.C. announces that a class ... or the "Company") (NYSE: PLL ).,The lawsuit, filed ... of New York, seeks damages for violations of federal ... securities between April,20, 2007 and August 8, 2007 (the ...
... 11 Just one week after,Cover All Pennsylvanians, ... in the Legislature, Governor Edward G.,Rendell today held ... of his,statewide "Tour to Insure." The five-day, nine-stop ... costs and expand coverage. Cambria County has the,15th ...
Cached Medicine News:Health News:GordonsJewelers.com Introduces The Pink Collection in Honor of Breast Cancer Awareness Month 2Health News:Dr. Stephen Paget, Physician-in-Chief and Chairman, Division of Rheumatology, at Hospital for Special Surgery is Available to Comment on a Recent CDC Study on the Impact of Arthritis in the Work Place 2Health News:Sutter Violating State Safety Laws on Assuring Proper Competency Validation of Strike Staff, Say RNs 2Health News:Nasdaq Informs Synutra that the Company's Filing Delinquency has been Cured 2Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 2Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 3Health News:In Johnstown Governor Rendell Launches 'Tour to Insure;' Urges Passage of Plan to Give Access to Affordable Health Insurance 2Health News:In Johnstown Governor Rendell Launches 'Tour to Insure;' Urges Passage of Plan to Give Access to Affordable Health Insurance 3
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: